Julio Echarte-Morales MD , Pedro Cepas-Guillén MD, PhD , Dabit Arzamendi MD, PhD , Vanessa Moñivas MD, PhD , Fernando Carrasco-Chinchilla MD, PhD , Manuel Pan MD, PhD , Luis Nombela-Franco MD, PhD , Isaac Pascual MD, PhD , Tomás Benito-González MD , Ruth Pérez MD , Iván Gómez-Blázquez MD , Ignacio J. Amat-Santos MD, PhD , Ignacio Cruz-González MD, PhD , Ángel Sánchez-Recalde MD, PhD , Berenice Caneiro-Queija MD , Ana Belén Cid Álvarez MD, PhD , Manuel Barreiro-Pérez MD, PhD , Laura Sanchis MD, PhD , Chi Hion Li MD , María del Trigo MD, PhD , Rodrigo Estévez-Loureiro MD, PhD
{"title":"One-Year Recurrent Tricuspid Regurgitation After Successful Transcatheter Edge to Edge Repair: The TRI-SPA Registry","authors":"Julio Echarte-Morales MD , Pedro Cepas-Guillén MD, PhD , Dabit Arzamendi MD, PhD , Vanessa Moñivas MD, PhD , Fernando Carrasco-Chinchilla MD, PhD , Manuel Pan MD, PhD , Luis Nombela-Franco MD, PhD , Isaac Pascual MD, PhD , Tomás Benito-González MD , Ruth Pérez MD , Iván Gómez-Blázquez MD , Ignacio J. Amat-Santos MD, PhD , Ignacio Cruz-González MD, PhD , Ángel Sánchez-Recalde MD, PhD , Berenice Caneiro-Queija MD , Ana Belén Cid Álvarez MD, PhD , Manuel Barreiro-Pérez MD, PhD , Laura Sanchis MD, PhD , Chi Hion Li MD , María del Trigo MD, PhD , Rodrigo Estévez-Loureiro MD, PhD","doi":"10.1016/j.amjcard.2025.02.010","DOIUrl":null,"url":null,"abstract":"<div><div>Recurrent tricuspid regurgitation (TR) following transcatheter edge-to-edge repair (TEER) has not been thoroughly investigated. We aimed to examine the predictive factors and mid-term outcomes of recurrent TR following successful TEER. Procedural success was defined as the reduction of TR grade to ≤2+, assessed at discharge. Recurrence of TR was defined as TR grade 3+ or worse at 1 year after initially successful TEER. The primary endpoint of this study was the composite of all-cause mortality and heart failure (HF) hospitalization at 2 years-follow up. Among 163 T-TEER patients with a reduction in TR to ≤2+, 37 patients developed recurrent TR within the first 12 months (76% females, mean age 75.5 ± 8.3 years). Fractional area change (odds ratio, 1.05; p = 0.013), residual TR2+ (odds ratio, 5.08; p = 0.002) and primary TR etiology (odds ratio, 3.45, p = 0.043) were independent predictors of recurrent TR. Over a median follow-up of 18.4 months, the primary endpoint occurred in 11 (13.5%) and 17 (20.7%) of patients in the nonrecurrent and recurrent TR groups, respectively, with a hazard ratio of 2.39 (1.09 to 5.26, p = 0.030). In the survival analysis, there was a strong tendency toward higher rates of freedom from the primary endpoint in nonrecurrent TR patients (84.5% vs 73.2%; p = 0.066), mainly driven by lower rates of HF hospitalization (79.8% vs 65.2%; log-rank p = 0.048) compared to patients with recurrent TR. In conclusion, recurrent TR was associated with worse outcomes. Right ventricular fractional area change, residual TR and primary TR were independent predictors for recurrent TR.</div></div>","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":"243 ","pages":"Pages 50-58"},"PeriodicalIF":2.1000,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Cardiology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0002914925000840","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Recurrent tricuspid regurgitation (TR) following transcatheter edge-to-edge repair (TEER) has not been thoroughly investigated. We aimed to examine the predictive factors and mid-term outcomes of recurrent TR following successful TEER. Procedural success was defined as the reduction of TR grade to ≤2+, assessed at discharge. Recurrence of TR was defined as TR grade 3+ or worse at 1 year after initially successful TEER. The primary endpoint of this study was the composite of all-cause mortality and heart failure (HF) hospitalization at 2 years-follow up. Among 163 T-TEER patients with a reduction in TR to ≤2+, 37 patients developed recurrent TR within the first 12 months (76% females, mean age 75.5 ± 8.3 years). Fractional area change (odds ratio, 1.05; p = 0.013), residual TR2+ (odds ratio, 5.08; p = 0.002) and primary TR etiology (odds ratio, 3.45, p = 0.043) were independent predictors of recurrent TR. Over a median follow-up of 18.4 months, the primary endpoint occurred in 11 (13.5%) and 17 (20.7%) of patients in the nonrecurrent and recurrent TR groups, respectively, with a hazard ratio of 2.39 (1.09 to 5.26, p = 0.030). In the survival analysis, there was a strong tendency toward higher rates of freedom from the primary endpoint in nonrecurrent TR patients (84.5% vs 73.2%; p = 0.066), mainly driven by lower rates of HF hospitalization (79.8% vs 65.2%; log-rank p = 0.048) compared to patients with recurrent TR. In conclusion, recurrent TR was associated with worse outcomes. Right ventricular fractional area change, residual TR and primary TR were independent predictors for recurrent TR.
经导管边缘到边缘修复(TEER)后复发性三尖瓣反流(TR)尚未被彻底研究。我们的目的是研究TEER成功后复发性TR的预测因素和中期预后。手术成功的定义是在出院时评估TR等级降至≤2+。TR复发定义为在最初成功的TEER后一年TR分级为3+或更差。本研究的主要终点是随访2年的全因死亡率和心力衰竭住院率。163例TR降低至≤2+的T-TEER患者中,37例患者在前12个月内发生复发TR(76%为女性,平均年龄75.5±8.3岁)。分数面积变化(优势比,1.05;P=0.013),残余TR2+(优势比5.08;P=0.002)和原发性TR病因(优势比为3.45,P=0.043)是TR复发的独立预测因素。在18.4个月的中位随访中,非复发和复发TR组分别有11例(13.5%)和17例(20.7%)患者出现主要终点,风险比为2.39 (1.09-5.26,P=0.030)。在生存分析中,非复发性TR患者的主要终点自由率有较高的趋势(84.5% vs. 73.2%;P=0.066),主要是由于HF住院率较低(79.8% vs. 65.2%;log-rank P=0.048)。总之,复发性TR与较差的预后相关。右心室面积分数改变、残余TR和原发TR是复发性TR的独立预测因子。
期刊介绍:
Published 24 times a year, The American Journal of Cardiology® is an independent journal designed for cardiovascular disease specialists and internists with a subspecialty in cardiology throughout the world. AJC is an independent, scientific, peer-reviewed journal of original articles that focus on the practical, clinical approach to the diagnosis and treatment of cardiovascular disease. AJC has one of the fastest acceptance to publication times in Cardiology. Features report on systemic hypertension, methodology, drugs, pacing, arrhythmia, preventive cardiology, congestive heart failure, valvular heart disease, congenital heart disease, and cardiomyopathy. Also included are editorials, readers'' comments, and symposia.